Home Cart Sign in  
Chemical Structure| 7432-28-2 Chemical Structure| 7432-28-2

Structure of Schisandrin
CAS No.: 7432-28-2

Chemical Structure| 7432-28-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Schizandrin is a natural product possessing antioxidant and anti-inflammatory activities.

Synonyms: Schizandrin; Schizandrol; Wuweizins

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Schisandrin

CAS No. :7432-28-2
Formula : C24H32O7
M.W : 432.51
SMILES Code : O[C@]1(C)[C@@H](C)CC2=CC(OC)=C(OC)C(OC)=C2C3=C(OC)C(OC)=C(OC)C=C3C1
Synonyms :
Schizandrin; Schizandrol; Wuweizins

Safety of Schisandrin

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H332-H372-H400
Precautionary Statements:P260-P264-P270-P273-P280-P301+P312+P330-P304+P312-P305+P351+P338-P314-P337+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Primary cortical neurons 1 µM 18 days Promote neuronal maturation and axon growth Molecules. 2021 Dec 9;26(24):7466
RAW 264.7 macrophages 50, 100, 200 µM 1 hour pretreatment followed by 24 hours LPS stimulation Inhibited LPS-induced NO and PGE2 production, downregulated iNOS and COX-2 mRNA and protein expression Int J Mol Med. 2018 Jan;41(1):264-274
Bone marrow-derived macrophages (BMMs) 200 µM 2 days To evaluate the effect of Schisandrin A on BMMs apoptosis, results showed 200 μmol/L concentration did not induce apoptosis Cell Prolif. 2020 Oct;53(10):e12882.
BEAS‑2B 0, 25, 50, 75, 100 µM 24 hours SchA reduced the viability of BEAS‑2B cells in a concentration-dependent manner. Int J Mol Med. 2021 Dec;48(6):214.
H1299 0, 25, 50, 75, 100 µM 24 hours SchA reduced the viability of H1299 cells in a concentration-dependent manner. Int J Mol Med. 2021 Dec;48(6):214.
H1975 0, 25, 50, 75, 100 µM 24 hours SchA reduced the viability of H1975 cells in a concentration-dependent manner. Int J Mol Med. 2021 Dec;48(6):214.
A549 0, 25, 50, 75, 100 µM 24 hours SchA reduced the viability of A549 cells in a concentration-dependent manner. Int J Mol Med. 2021 Dec;48(6):214.
Rat chondrocytes 25, 50 µM 24 hours To evaluate the effects of Schisandrin A on IL-1β-induced inflammation and cartilage degradation. Results showed that Schisandrin A could suppress IL-1β-induced production of NO and PGE2, downregulate iNOS and COX2 expression, inhibit MMPs and ADAMTS5 expression, and reverse IL-1β-induced downregulation of Collagen II, Aggrecan, and Sox9. Front Pharmacol. 2019 Jan 29;10:41
Bone marrow-derived macrophages (BMMs) 0, 50, 100, 150, 200, 400 µM 24, 48, 72 hours To evaluate the effect of Schisandrin A on BMMs cell viability, results showed no significant effect on cell viability below 200 μmol/L Cell Prolif. 2020 Oct;53(10):e12882.
THP-1 cells 20/40/80 µM 4 hours To investigate the effect of SCH on NLRP3 inflammasome activation in THP-1 cells, results showed that SCH could inhibit NLRP3 inflammasome activation. Chin Med. 2023 Sep 6;18(1):112
Spd2 cells 5, 10, 20 mM 48 hours To evaluate the effect of Schisandrin A on the viability of Spd2 cells. Results showed that Schisandrin A promoted the proliferation of testicular interstitial cells at concentrations of 10–40 mmol/L, with the best effect observed at 10 mmol/L. Acta Pharm Sin B. 2023 Jun;13(6):2765-2777.
Rat colonic smooth muscle cells 0.5-10 µM 5 minutes To investigate the inhibitory effect of Schisandrin on spontaneous contraction of rat colon, results showed that Schisandrin inhibited colonic spontaneous contraction in a concentration-dependent manner with an EC50 of 1.66 μM. Phytomedicine. 2011 Aug 15;18(11):998-1005
Neural progenitor cells (NPCs) 1 µM 72 hours Promote the proliferation of neural progenitor cells Molecules. 2021 Dec 9;26(24):7466

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Ovariectomy-induced osteoporosis model Injection 100 mg/kg Every other day for 6 weeks To evaluate the effect of Schisandrin A on ovariectomy-induced osteoporosis, results showed it significantly reduced bone loss Cell Prolif. 2020 Oct;53(10):e12882.
C57/BL6 mice Ischemic brain injury model Intraperitoneal injection 12 mg/kg Once daily for 3 weeks Promote neural progenitor cell proliferation and nerve fiber regeneration Molecules. 2021 Dec 9;26(24):7466
APP/PS1 transgenic mice Alzheimer's disease model Intragastrically 2 mg/kg/day Once daily for 2 weeks Schisandrin ameliorated learning and memory impairments in APP/PS1 mice and significantly decreased Aβ deposition in the hippocampus. Additionally, Schisandrin treatment restored the abnormal levels of neurotransmitters and their metabolites in the brain. Acta Pharmacol Sin. 2018 Apr;39(4):616-625
C57BL/6 mice DSS-induced ulcerative colitis model Gavage 20, 40, 80 mg/kg/d Once daily for 7 days To evaluate the therapeutic effect of SCH on ulcerative colitis, results showed that SCH significantly alleviated colitis symptoms, reduced inflammatory factors, and restored gut microbiota balance. Chin Med. 2023 Sep 6;18(1):112
Sprague-Dawley rats OA model induced by anterior cruciate ligament transection and partial medial meniscectomy Intra-articular injection 50 μM Once weekly for one month To evaluate the protective effects of Schisandrin A on cartilage damage in OA model. Results showed that Schisandrin A significantly alleviated joint damage and reduced cartilage destruction. Front Pharmacol. 2019 Jan 29;10:41

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.31mL

0.46mL

0.23mL

11.56mL

2.31mL

1.16mL

23.12mL

4.62mL

2.31mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories